• Je něco špatně v tomto záznamu ?

Gene silencing delivery systems for the treatment of pancreatic cancer: Where and what to target next

D. Vetvicka, L. Sivak, CM. Jogdeo, R. Kumar, R. Khan, Y. Hang, D. Oupický

. 2021 ; 331 (-) : 246-259. [pub] 20210120

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025971

Despite intensive research efforts and development of numerous new anticancer drugs and treatment strategies over the past decades, there has been only very limited improvement in overall patient survival and in effective treatment options for pancreatic cancer. Current chemotherapy improves survival in terms of months and death rates in pancreatic cancer patients are almost equivalent to incidence rates. It is imperative to develop new therapeutic approaches. Among them, gene silencing shows promise of effectiveness in both tumor cells and stromal cells by inhibiting tumor-promoting genes. This review summarizes potential targets for gene silencing in both pancreatic cancer cells and abundant stromal cells focusing on non-viral delivery systems for small RNAs and discusses the potential immunological implications. The review concludes with the importance of multifactorial therapy of pancreatic cancer.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025971
003      
CZ-PrNML
005      
20211026133328.0
007      
ta
008      
211013s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jconrel.2021.01.020 $2 doi
035    __
$a (PubMed)33482273
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Vetvicka, David $u Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, United States; Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Salmovska 1, Prague 2 12000, Czech Republic
245    10
$a Gene silencing delivery systems for the treatment of pancreatic cancer: Where and what to target next / $c D. Vetvicka, L. Sivak, CM. Jogdeo, R. Kumar, R. Khan, Y. Hang, D. Oupický
520    9_
$a Despite intensive research efforts and development of numerous new anticancer drugs and treatment strategies over the past decades, there has been only very limited improvement in overall patient survival and in effective treatment options for pancreatic cancer. Current chemotherapy improves survival in terms of months and death rates in pancreatic cancer patients are almost equivalent to incidence rates. It is imperative to develop new therapeutic approaches. Among them, gene silencing shows promise of effectiveness in both tumor cells and stromal cells by inhibiting tumor-promoting genes. This review summarizes potential targets for gene silencing in both pancreatic cancer cells and abundant stromal cells focusing on non-viral delivery systems for small RNAs and discusses the potential immunological implications. The review concludes with the importance of multifactorial therapy of pancreatic cancer.
650    12
$a antitumorózní látky $x terapeutické užití $7 D000970
650    _2
$a umlčování genů $7 D020868
650    _2
$a lidé $7 D006801
650    12
$a nádory slinivky břišní $x farmakoterapie $x terapie $7 D010190
650    _2
$a buňky stromatu $7 D017154
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Sivak, Ladislav $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, Brno CZ-61300, Czech Republic
700    1_
$a Jogdeo, Chinmay M $u Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, United States
700    1_
$a Kumar, Raj $u Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, United States
700    1_
$a Khan, Rubayat $u Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, United States
700    1_
$a Hang, Yu $u Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, United States
700    1_
$a Oupický, David $u Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, United States. Electronic address: david.oupicky@unmc.edu
773    0_
$w MED00002621 $t Journal of controlled release : official journal of the Controlled Release Society $x 1873-4995 $g Roč. 331, č. - (2021), s. 246-259
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33482273 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133334 $b ABA008
999    __
$a ok $b bmc $g 1714857 $s 1146478
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 331 $c - $d 246-259 $e 20210120 $i 1873-4995 $m Journal of controlled release $n J Controlled Release $x MED00002621
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...